Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NeoGenomics Laboratories (NEO)

NeoGenomics Q2 2026 revenue rises 11% to $202 million; full-year guidance raised

Positive Impact 4 of 5 guidance Written later

NeoGenomics reported second-quarter 2026 revenue of $202 million, up 11% from a year earlier, and GAAP net income of $2 million compared with a net loss of $45 million in the same quarter of 2025. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, which signals improved expectations for shareholders, though GAAP net income includes an $11 million gain on debt extinguishment.

Key points

  • Q2 2026 revenue was $202 million, up 11%; clinical services revenue rose 14% and NGS revenue rose 26%.
  • GAAP net income was $2 million versus a $45 million net loss a year earlier, including an $11 million gain on extinguishment of debt.
  • Adjusted EBITDA rose 36% to $14 million in the quarter.
  • Full-year 2026 revenue guidance was raised to $802 million to $806 million from $797 million to $803 million; adjusted EBITDA guidance rose to $56 million to $58 million from $55 million to $57 million.

The filing

CompanyNeoGenomics Laboratories (NEO)
Form8-K, current report
Filed with the SECJul 28, 2026, 4:05 PM ET
Accession number0001077183-26-000058

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.